Promoted Content
Promoted Content

Find Approved Drugs for Infections and Infectious Diseases in Clinical Development in UNITED STATES

Loading...

All Data

Filters Filter refresh
×
FILTER DATA :
News Type filter
    Company filter
      Product Type filter
        Deal Size filter
          Upfront Payment filter
            refresh

            Product Type Full Screen

            Companies Full Screen

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): Remdesivir

            Therapeutic Area: Infections and Infectious Diseases Product Name: Veklury

            Highest Development Status: Approved Product Type: Small molecule

            Partner/Sponsor/Collaborator: Gilead Sciences

            Deal Size: Undisclosed Upfront Cash: Undisclosed

            Deal Type: Agreement August 07, 2020

            Details:

            Under the terms of the agreement, Pfizer will provide contract manufacturing services at Pfizer’s McPherson, Kansas facility to manufacture and supply remdesivir for Gilead.

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): Remdesivir

            Therapeutic Area: Infections and Infectious Diseases Product Name: Veklury

            Highest Development Status: Approved Product Type: Small molecule

            Partner/Sponsor/Collaborator: Not Applicable

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable October 22, 2020

            Details:

            Previously authorized by the FDA for emergency use to treat COVID-19, Veklury is now the first and only approved COVID-19 treatment in the United States.

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): Omadacycline Tosylate

            Therapeutic Area: Infections and Infectious Diseases Product Name: Nuzyra

            Highest Development Status: Approved Product Type: Small molecule

            Partner/Sponsor/Collaborator: Not Applicable

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable October 21, 2020

            Details:

            Key highlights include data on NUZYRA as an alternative to standard of care to reduce Clostridioides Difficile infections and real-world experience with NUZYRA for nontuberculous mycobacterial and MDR/XDR gram negative infections.

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): Remdesivir

            Therapeutic Area: Infections and Infectious Diseases Product Name: Veklury

            Highest Development Status: Approved Product Type: Small molecule

            Partner/Sponsor/Collaborator: World Health Organization

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable October 16, 2020

            Details:

            The WHO released preliminary results from a trial involving 11,266 COVID-19 patients in 30 countries who were treated with one of four drug regimens, including remdesivir. Remdesivir appeared to have little or no effect on hospitalized COVID-19” patients.

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): Atoltivimab,Maftivimab,Odesivimab-ebgn

            Therapeutic Area: Infections and Infectious Diseases Product Name: Inmazeb

            Highest Development Status: Approved Product Type: Large molecule

            Partner/Sponsor/Collaborator: Not Applicable

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable October 14, 2020

            Details:

            In a large clinical trial, Inmazeb showed superiority compared to other investigational agents (ZMapp and remdesivir) with respect to mortality; treatment was most effective when given early in the course of disease.

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): Cefiderocol sulfate tosylate

            Therapeutic Area: Infections and Infectious Diseases Product Name: Fetroja

            Highest Development Status: Approved Product Type: Small molecule

            Partner/Sponsor/Collaborator: Not Applicable

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable October 13, 2020

            Details:

            Publication of two studies in The Lancet Infectious Diseases journal has shown the efficacy and safety of FETROJA for some of the most difficult-to-treat Gram-negative bacterial infections, including nosocomial pneumonia, bloodstream infections, sepsis, and Complicated UTIs.

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): Remdesivir

            Therapeutic Area: Infections and Infectious Diseases Product Name: Veklury

            Highest Development Status: Approved Product Type: Small molecule

            Partner/Sponsor/Collaborator: The European Commission

            Deal Size: Undisclosed Upfront Cash: Undisclosed

            Deal Type: Agreement October 08, 2020

            Details:

            The agreement covers purchases of Veklury over the next six months and has the option to be extended. In the EU, EEA and UK, Veklury is indicated for the treatment of COVID-19 in adult and adolescent patients with pneumonia requiring supplemental oxygen.

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): Remdesivir

            Therapeutic Area: Infections and Infectious Diseases Product Name: Veklury

            Highest Development Status: Approved Product Type: Small molecule

            Partner/Sponsor/Collaborator: Not Applicable

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable October 08, 2020

            Details:

            Treatment with Veklury resulted in consistent, clinically meaningful improvements across multiple outcome assessments compared with placebo in COVID-19 patients.

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): Obiltoxaximab

            Therapeutic Area: Infections and Infectious Diseases Product Name: Obiltoxaximab SFL

            Highest Development Status: Approved Product Type: Large molecule

            Partner/Sponsor/Collaborator: Not Applicable

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable October 08, 2020

            Details:

            Obiltoxaximab SFL is indicated in all age groups in combination with appropriate antibacterial drugs for the treatment of inhalational anthrax due to Bacillus anthracis; and for post-exposure prophylaxis of inhalational anthrax when alternative therapies are not available.

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): Tecovirimat

            Therapeutic Area: Infections and Infectious Diseases Product Name: Tpoxx

            Highest Development Status: Approved Product Type: Small molecule

            Partner/Sponsor/Collaborator: Public Health Agency of Canada

            Deal Size: Undisclosed Upfront Cash: Undisclosed

            Deal Type: Agreement October 08, 2020

            Details:

            Public Health Agency of Canada (PHAC) has issued an advanced contract award notice (ACAN), indicating that the PHAC intends to purchase up to 33,300 courses of oral TPOXX® (tecovirimat) within five years as specified in the ACAN.

            PharmaCompass